Ruxolitinib in Combination With Venetoclax With and Without Azacitidine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This phase I trial studies the side effects and best dose of ruxolitinib when given together with venetoclax and compares the effect of ruxolitinib in combination with venetoclax to venetoclax and azacitidine in treating patients with acute myeloid leukemia (AML) that has come back (relapsed) or has not responded to treatment (refractory). Ruxolitinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Azacitidine stops cells from making deoxyribonucleic acid and may kill cancer cells. It is a type of antimetabolite. Venetoclax is in a class of medications called B-cell lymphoma-2 (BCL-2) inhibitors. It may stop the growth of cancer cells by blocking Bcl-2, a protein needed for cancer cell survival. Giving ruxolitinib in combination with venetoclax and azacitidine may be safe, tolerable, and/or effective compared to ruxolitinib with venetoclax in treating patients with relapsed or refractory AML.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Pacjent rozumie i zgadza się wziąć udział w badaniu.
- •Pacjent ma co najmniej 18 lat.
- •U pacjenta stwierdzono ostrą białaczkę szpikową (AML), która powróciła lub nie reaguje na leczenie, lub wtórną AML.
- •Pacjent wcześniej otrzymywał leczenie na AML.
- •Pacjent może przyjmować i przyswajać leki doustne.
- •Pacjent musi stosować skuteczną metodę antykoncepcji.
- •Pacjent ma odpowiednią wydolność nerek (filtracja co najmniej 30 ml/min).
✗ Disqualifies
- •Pacjent ma poważne problemy z sercem.
- •Pacjent ma poważne problemy z płucami.
- •Pacjent ma problemy z wątrobą.
- •Pacjent ogólnie czuje się źle (w skali ECOG 3 lub 4).
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- July 6, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (3)
Ohio State University Comprehensive Cancer Center
Columbus, United States
OHSU Knight Cancer Institute
Portland, United States
UT Southwestern/Simmons Cancer Center-Dallas
Dallas, United States
Trial contact
Jennifer N. Saultz, MD
Jennifer N. Saultz, MD
PRINCIPAL_INVESTIGATOR
Contact information from ClinicalTrials.gov. Contact in English.
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/7/2026.